1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105192, NCT00334282
|
|
2.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG102616, NCT00244764
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-62043, GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG20006, NCT00256880
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104450, VEG104450, NCT00281632
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG20007, NCT00347919
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105290, NCT00367679
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105281, NCT00430781
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTC-0602, NABTC-06-02, 737754, NCT00459381, NCI-07-C-0138
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0623, N0623, NCT00459862
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-058, 7640, PMH-10036920, PHL-058, NCT00486642
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-057, 7638, PHL-057, NCT00509587
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 109609, NCT00549328
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG110190, NCT00561795
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CASE-CWRU-100231, GSK-VEG10003, GSK-RM2002/00345/02, CWRU-GLAX-1Y02, CWRU-1Y02, NCT00060151, CASE-100231
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG10006, NCT00158782
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG10005, NCT00363194
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105424, NCT00387387
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG10007, 10007, NCT00401583
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG10004, NCT00478725
|
